---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-034218"
form_type: "8-K"
ticker: "ADTX"
cik: "0001726711"
company_name: "Aditxt, Inc."
filed_at: "2025-04-22T23:59:59+00:00"
generated_at: "2026-05-23T09:25:56.689536+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aditxt subsidiary Pearsanta receives IRB approval to begin clinical studies for endometriosis blood test

## Summary
- Pearsanta received IRB approval to start clinical studies for a blood-based diagnostic test for endometriosis using mitochondrial DNA analysis.
- Test uses Mitomic technology to detect disruptions in mitochondrial DNA from a blood sample; aims to replace invasive laparoscopic diagnosis.
- Clinical validation targets ~100 samples from OB-GYN sites; commercial launch as an LDT targeted for end of June 2025.
- Next test in pipeline is for prostate cancer; Richmond CLIA/CAP lab to process samples.
- Collaborating with Evofem to recruit OB-GYN sites for the study; highlights synergies between subsidiaries.

## SEC filing metadata
- accession: 0001213900-25-034218
- form_type: 8-K
- ticker: ADTX
- cik: 0001726711
- company_name: Aditxt, Inc.
- filed_at: 2025-04-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1726711/000121390025034218/0001213900-25-034218-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1726711/000121390025034218/ea0239164-8k_aditxt.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-034218
- JSON: https://secwatch.observer/filing/0001213900-25-034218.json
- Plain text: https://secwatch.observer/filing/0001213900-25-034218.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.